Literature DB >> 22771240

Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients.

Gonzalo Laje, Níall Lally, Daniel Mathews, Nancy Brutsche, Anat Chemerinski, Nirmala Akula, Benjamin Kelmendi, Arthur Simen, Francis J McMahon, Gerard Sanacora, Carlos Zarate.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22771240      PMCID： PMC3786174          DOI： 10.1016/j.biopsych.2012.05.031

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  15 in total

1.  mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.

Authors:  Nanxin Li; Boyoung Lee; Rong-Jian Liu; Mounira Banasr; Jason M Dwyer; Masaaki Iwata; Xiao-Yuan Li; George Aghajanian; Ronald S Duman
Journal:  Science       Date:  2010-08-20       Impact factor: 47.728

Review 2.  Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.

Authors:  Gerard Sanacora; Giulia Treccani; Maurizio Popoli
Journal:  Neuropharmacology       Date:  2011-08-03       Impact factor: 5.250

3.  A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.

Authors:  Nancy Diazgranados; Lobna Ibrahim; Nancy E Brutsche; Andrew Newberg; Phillip Kronstein; Sami Khalife; William A Kammerer; Zenaide Quezado; David A Luckenbaugh; Giacomo Salvadore; Rodrigo Machado-Vieira; Husseini K Manji; Carlos A Zarate
Journal:  Arch Gen Psychiatry       Date:  2010-08

4.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Authors:  Carlos A Zarate; Jaskaran B Singh; Paul J Carlson; Nancy E Brutsche; Rezvan Ameli; David A Luckenbaugh; Dennis S Charney; Husseini K Manji
Journal:  Arch Gen Psychiatry       Date:  2006-08

5.  The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS.

Authors:  Gerald W Valentine; Graeme F Mason; Rosane Gomez; Madonna Fasula; June Watzl; Brian Pittman; John H Krystal; Gerard Sanacora
Journal:  Psychiatry Res       Date:  2011-01-12       Impact factor: 3.222

6.  Voluntary exercise induces a BDNF-mediated mechanism that promotes neuroplasticity.

Authors:  Fernando Gómez-Pinilla; Zhe Ying; Roland R Roy; Raffaella Molteni; V Reggie Edgerton
Journal:  J Neurophysiol       Date:  2002-11       Impact factor: 2.714

7.  Brain-derived neurotrophic factor ( BDNF) gene: no major impact on antidepressant treatment response.

Authors:  Katharina Domschke; Bruce Lawford; Gonzalo Laje; Klaus Berger; Ross Young; Phillip Morris; Jürgen Deckert; Volker Arolt; Francis J McMahon; Bernhard T Baune
Journal:  Int J Neuropsychopharmacol       Date:  2009-02-23       Impact factor: 5.176

8.  Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments.

Authors:  M Nibuya; S Morinobu; R S Duman
Journal:  J Neurosci       Date:  1995-11       Impact factor: 6.167

Review 9.  New insights into BDNF function in depression and anxiety.

Authors:  Keri Martinowich; Husseini Manji; Bai Lu
Journal:  Nat Neurosci       Date:  2007-09       Impact factor: 24.884

10.  NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.

Authors:  Anita E Autry; Megumi Adachi; Elena Nosyreva; Elisa S Na; Maarten F Los; Peng-fei Cheng; Ege T Kavalali; Lisa M Monteggia
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962
View more
  87 in total

Review 1.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

2.  Activation of a ventral hippocampus-medial prefrontal cortex pathway is both necessary and sufficient for an antidepressant response to ketamine.

Authors:  F R Carreno; J J Donegan; A M Boley; A Shah; M DeGuzman; A Frazer; D J Lodge
Journal:  Mol Psychiatry       Date:  2015-12-01       Impact factor: 15.992

3.  Increasing doses of ketamine curtail antidepressant responses and suppress associated synaptic signaling pathways.

Authors:  Ji-Woon Kim; Lisa M Monteggia
Journal:  Behav Brain Res       Date:  2019-11-21       Impact factor: 3.332

Review 4.  Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.

Authors:  Chadi G Abdallah; Lynnette A Averill; John H Krystal
Journal:  Ann N Y Acad Sci       Date:  2015-02-27       Impact factor: 5.691

5.  Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response.

Authors:  James W Murrough; Le-Ben Wan; Brian Iacoviello; Katherine A Collins; Carly Solon; Benjamin Glicksberg; Andrew M Perez; Sanjay J Mathew; Dennis S Charney; Dan V Iosifescu; Katherine E Burdick
Journal:  Psychopharmacology (Berl)       Date:  2013-09-11       Impact factor: 4.530

Review 6.  Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

Authors:  Mark J Niciu; Ioline D Henter; David A Luckenbaugh; Carlos A Zarate; Dennis S Charney
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

7.  Neurobiology of rapid acting antidepressants: role of BDNF and GSK-3β.

Authors:  Ronald S Duman; George K Aghajanian
Journal:  Neuropsychopharmacology       Date:  2014-01       Impact factor: 7.853

8.  Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures.

Authors:  Ashley E Lepack; Eunyoung Bang; Boyoung Lee; Jason M Dwyer; Ronald S Duman
Journal:  Neuropharmacology       Date:  2016-09-12       Impact factor: 5.250

Review 9.  A brief history of the development of antidepressant drugs: from monoamines to glutamate.

Authors:  Todd M Hillhouse; Joseph H Porter
Journal:  Exp Clin Psychopharmacol       Date:  2015-02       Impact factor: 3.157

Review 10.  Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.

Authors:  Saurabh S Kokane; Ross J Armant; Carlos A Bolaños-Guzmán; Linda I Perrotti
Journal:  Behav Brain Res       Date:  2020-02-13       Impact factor: 3.332
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.